PMID- 11752122
OWN - NLM
STAT- MEDLINE
DCOM- 20020124
LR  - 20190607
IS  - 0022-3565 (Print)
IS  - 0022-3565 (Linking)
VI  - 300
IP  - 1
DP  - 2002 Jan
TI  - 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: 
      psychomotor performance, subjective effects, and pharmacokinetics.
PG  - 236-44
AB  - 3,4-Methylenedioxymethamphetamine (MDMA) is frequently consumed in association 
      with alcohol. The effect of this combination in humans has not been previously 
      investigated. Nine male healthy volunteers received single oral doses of 100 mg 
      of MDMA plus 0.8 g/kg ethanol, 100 mg of MDMA, 0.8 g/kg of ethanol, and placebo 
      in a double blind, double dummy, randomized crossover trial. Measurements 
      included psychomotor performance, subjective effects, and pharmacokinetics. 
      Plasma concentrations of MDMA showed a 13% increase after the use of alcohol, 
      whereas plasma concentrations of alcohol showed a 9 to 15% decrease after MDMA 
      administration. The MDMA-alcohol combination induced longer lasting euphoria and 
      well being than MDMA or alcohol alone. MDMA reversed the subjective sedation 
      induced by alcohol but did not reduce drunkenness feelings. MDMA did not reverse 
      the actions of alcohol on psychomotor abilities. Combined use of MDMA and alcohol 
      causes dissociation between subjective and objective sedation. Subjects may feel 
      euphoric and less sedated and might have the feeling of doing better, but actual 
      performance ability continues to be impaired by the effect of alcohol. 
      Confirmation of these findings in further studies will be highly relevant in 
      terms of road safety.
FAU - Hernandez-Lopez, Candido
AU  - Hernandez-Lopez C
AD  - Unit of Pharmacology, Institut Municipal d'Investigacio Medica, Hospital del Mar, 
      Barcelona, Spain.
FAU - Farre, Magi
AU  - Farre M
FAU - Roset, Pere N
AU  - Roset PN
FAU - Menoyo, Esther
AU  - Menoyo E
FAU - Pizarro, Nieves
AU  - Pizarro N
FAU - Ortuno, Jordi
AU  - Ortuno J
FAU - Torrens, Marta
AU  - Torrens M
FAU - Cami, Jordi
AU  - Cami J
FAU - de La Torre, Rafael
AU  - de La Torre R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Pharmacol Exp Ther
JT  - The Journal of pharmacology and experimental therapeutics
JID - 0376362
RN  - 0 (Central Nervous System Depressants)
RN  - 0 (Hallucinogens)
RN  - 3K9958V90M (Ethanol)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adult
MH  - Affect/*drug effects
MH  - Area Under Curve
MH  - Central Nervous System Depressants/adverse effects/pharmacokinetics/*pharmacology
MH  - Double-Blind Method
MH  - Drug Interactions
MH  - Ethanol/adverse effects/pharmacokinetics/*pharmacology
MH  - Euphoria/drug effects
MH  - Hallucinogens/adverse effects/pharmacokinetics/*pharmacology
MH  - Humans
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/adverse 
      effects/pharmacokinetics/*pharmacology
MH  - Psychomotor Performance/*drug effects
EDAT- 2001/12/26 10:00
MHDA- 2002/01/25 10:01
CRDT- 2001/12/26 10:00
PHST- 2001/12/26 10:00 [pubmed]
PHST- 2002/01/25 10:01 [medline]
PHST- 2001/12/26 10:00 [entrez]
AID - 10.1124/jpet.300.1.236 [doi]
PST - ppublish
SO  - J Pharmacol Exp Ther. 2002 Jan;300(1):236-44. doi: 10.1124/jpet.300.1.236.